PT LLOYD PHARMA INDONESIA

What PT LLOYD PHARMA INDONESIA does

PT Lloyd Pharma Indonesia (LPI) is a privately held Indonesian pharmaceutical manufacturer founded in February 2016 and headquartered in Tangerang, Banten. The company manufactures non-betalactam solid dosage products (caplets, capsules, tablets) at its Tangerang facility and holds more than 30 POM/DKL/DBL product registrations with the Indonesian FDA (BPOM) spanning anti-inflammatory, analgesic, antibacterial, antiviral, antidiarrheal, antiallergic, antacid, mucolytic, anti-asthmatic, antidiabetic, anti-hypertensive, antihistamine, and vitamin/mineral supplement categories. Its portfolio includes branded generics such as Bidaxtam, Bimagen, Bimactrim, Coxiloid, Lodixon, Entegard, Vitacee Plus, Zenovit Gold, and the recently launched Sitavia (Sitagliptin) and Zamval (Amlodipine/Valsartan) lines.

The company operates a hybrid supply model: in-house manufacturing of non-betalactam solids is supplemented by finished-product imports from manufacturers in India and the Philippines and toll manufacturing partnerships with local Indonesian producers that enable betalactam and cephalosporin formats including syrups, suspensions, and sterile injections. Distribution is conducted domestically through a direct field sales motion with dedicated sales email and WhatsApp ordering, serving Indonesian pharmacies, hospitals, clinics, and end-patients.

Revenue is generated through one-time product sales of branded generics across the Indonesian market; pricing is not publicly disclosed and no funding rounds, parent company, or ownership structure are reported. The company has 11-50 employees, runs a lean digital presence (corporate website and Instagram), and conducts no disclosed M&A, international expansion, or AI-related initiatives. In August 2026, LPI issued a product recall for its Simvastatin medication, indicating active regulatory compliance and pharmacovigilance operations.

Name

PT LLOYD PHARMA INDONESIA

Legal name

PT Lloyd Pharma Indonesia

Website

https://lloydpharma.id

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

PT Lloyd Pharma Indonesia is a privately held Indonesian pharmaceutical manufacturer founded in 2016, producing branded generic medications in caplet, capsule, and tablet formats across multiple therapeutic categories for the domestic Indonesian healthcare market, supplemented by imports and toll manufacturing partnerships.

Ownership category

akta.pro rank

Headquarters

HQ city

Tangerang

HQ country

Indonesia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Manufacturing and Distribution: PT Lloyd Pharma Indonesia manufactures pharmaceutical products including non-betalactam solids, betalactam, and cephalosporin drugs (syrups, suspensions, sterile injections). The company also imports finished pharmaceutical products from manufacturers in India and Philippines, and utilizes local manufacturers for tolling drugs. Revenue is generated through product sales in the Indonesian market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

PT Lloyd Pharma Indonesia (LPI) is an Indonesian pharmaceutical manufacturer that started operations in February 2016 with non-betalactam solid dosage forms across 14 product registrations. The company has since expanded its portfolio through imported finished products from manufacturers in India and the Philippines, plus toll manufacturing arrangements with local Indonesian manufacturers to produce syrups, suspensions, and sterile injections of Betalactam and Cephalosporin drugs. The portfolio spans therapeutic categories including anti-inflammatory, analgesic, antibiotic, antiviral, antidiarrheal, antiallergic, antacid, mucolytic, anti-asthmatic, anti-obesity, anti-diabetic, anti-hypertensive, antihistamine, and vitamin/mineral supplements.

Product overview

PT Lloyd Pharma Indonesia is an Indonesian pharmaceutical manufacturer producing a diverse portfolio of prescription and OTC medications organized across three primary dosage form categories: Caplets (e.g., Bidaxtam, Bimagen, Biropyron, Entegard), Capsules (e.g., Vitacee Plus, Zenovit, Farmabion Gold), and Tablets (e.g., Lodixon, Neucompli, Coxiloid variants). The company's therapeutic offerings span anti-inflammatory drugs (Lodixon, Coxiloid, Methylprednisolone), antibacterial medications (Bimactrim, Bimaflox, Ciprofloxacin), analgesics (Bimagen, Paracetamol, Bimacyl), vitamins and minerals (Zenovit Gold, Neucompli, Biofamil Genio), respiratory treatments (Salmeflo, Lycopect, Stargrip), cardiovascular medications (Zamval), antidiabetics (Sitavia), and antivirals (Entegard). The company began non-betalactam solids manufacturing in February 2016 with 14 product registrations and has since expanded through imported finished products from India and the Philippines, toll manufacturing with local manufacturers, and additional drug formats including syrups, suspensions, and sterile injections of Betalactam and Cephalosporin products.

Differentiator

Problem solved

Functional benefit

Products and services

• Bidaxtam

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Reputable Manufacturing Companies in IndiacoreTechnology or Integration · 1 February 2016LPI imports finished pharmaceutical products from reputable manufacturing companies in India. This partnership enables the company to expand its product portfolio beyond its own manufacturing capabilities.
• Reputable Manufacturing Companies in the PhilippinescoreTechnology or Integration · 1 February 2016LPI imports finished pharmaceutical products from reputable manufacturing companies in the Philippines. This partnership complements the import portfolio alongside Indian manufacturers.
• Local Indonesian Manufacturers (Tolling Partners)coreTechnology or Integration · 1 February 2016LPI has tolling arrangements with local manufacturers in Indonesia for drug manufacturing. This enables the company to expand production capacity and product formats including syrups, suspensions, and sterile injections without significant capital investment in manufacturing facilities.

Scale indicators1 record

Recent moves7 records

Expansion highlights3 records

Direct peers

• PT Indofarma Tbk: Indonesian state-owned pharma manufacturer producing generics across antibiotics, anti-inflammatories, vitamins, and chronic disease categories. Closely comparable as a domestic generic manufacturer serving the same Indonesian prescription and OTC market.
• PT Kalbe Farma Tbk: Indonesia's largest pharmaceutical company, manufacturing a broad range of generic and branded prescription drugs across similar therapeutic categories (anti-infectives, cardiovascular, anti-diabetics, vitamins). Comparable as a domestic Indonesian pharma manufacturer competing for the same pharmacy and hospital channels.
• PT Errita Pharma: Indonesian pharmaceutical manufacturer with a portfolio of generic prescription and OTC products. Comparable as a domestic generic pharma peer of similar scale operating in the Indonesian market.
• PT Novell Pharmaceutical Laboratories: Indonesian pharmaceutical manufacturer producing generic prescription drugs across multiple therapeutic categories. Comparable as a smaller domestic generic manufacturer competing in similar Indonesian prescription channels.
• PT Sanbe Farma: Large Indonesian pharmaceutical manufacturer producing generic prescription drugs, OTC products, and sterile injectables. Comparable for the sterile-injection and betalactam/cephalosporin format overlap and for shared Indonesian distribution channels.
• PT Dexa Medica: Major Indonesian pharmaceutical manufacturer with a strong generic and branded-generic portfolio spanning similar therapeutic areas including antibiotics, anti-inflammatories, and chronic disease medications. Directly competes for prescription share with LPI's catalog.
• PT Soho Global Health: Indonesian pharmaceutical and consumer healthcare manufacturer with a generic prescription, OTC, and supplement portfolio. Comparable for the vitamin/supplement and prescription drug overlap and shared Indonesian distribution model.
• PT Meprofarm: Indonesian pharmaceutical manufacturer producing generic prescription drugs across multiple therapeutic categories including anti-infectives and chronic disease medications. Comparable as a domestic generic pharma peer of similar scale and Indonesian market focus.
• PT Phapros Tbk: Indonesian pharmaceutical manufacturer with a portfolio of generic prescription drugs including anti-infectives, anti-inflammatories, and vitamins. Comparable in scale and therapeutic focus as a domestic generic manufacturer.

Broad incumbents

• PT Kimia Farma Tbk: State-owned Indonesian pharmaceutical manufacturer and distributor with a broad generic prescription portfolio plus a national pharmacy chain. Comparable as a much larger incumbent producing overlapping generic molecules and operating across similar distribution channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• Instagraminstagram.com/lloyd.pharma
• LinkedInlinkedin.com/company/pt-lloyd-pharma-indonesia

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PT LLOYD PHARMA INDONESIA